463 related articles for article (PubMed ID: 17499461)
1. Silk fibroin mediated delivery of liposomal emodin to breast cancer cells.
Cheema SK; Gobin AS; Rhea R; Lopez-Berestein G; Newman RA; Mathur AB
Int J Pharm; 2007 Aug; 341(1-2):221-9. PubMed ID: 17499461
[TBL] [Abstract][Full Text] [Related]
2. Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin.
Zhang L; Chang CJ; Bacus SS; Hung MC
Cancer Res; 1995 Sep; 55(17):3890-6. PubMed ID: 7543819
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.
Zhang L; Lau YK; Xia W; Hortobagyi GN; Hung MC
Clin Cancer Res; 1999 Feb; 5(2):343-53. PubMed ID: 10037184
[TBL] [Abstract][Full Text] [Related]
4. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.
McGuire KP; Ngoubilly N; Neavyn M; Lanza-Jacoby S
J Surg Res; 2006 May; 132(2):208-13. PubMed ID: 16580691
[TBL] [Abstract][Full Text] [Related]
5. Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling.
Pan MH; Lin CC; Lin JK; Chen WJ
J Agric Food Chem; 2007 Jun; 55(13):5030-7. PubMed ID: 17539658
[TBL] [Abstract][Full Text] [Related]
6. Silk-fibroin-coated liposomes for long-term and targeted drug delivery.
Gobin AS; Rhea R; Newman RA; Mathur AB
Int J Nanomedicine; 2006; 1(1):81-7. PubMed ID: 17722265
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of HER2/neu receptor by solamargine enhances anticancer drug-mediated cytotoxicity in breast cancer cells with high-expressing HER2/neu.
Shiu LY; Liang CH; Huang YS; Sheu HM; Kuo KW
Cell Biol Toxicol; 2008 Jan; 24(1):1-10. PubMed ID: 17885815
[TBL] [Abstract][Full Text] [Related]
8. Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells.
Manuvakhova M; Thottassery JV; Hays S; Qu Z; Rentz SS; Westbrook L; Kern FG
Oncogene; 2006 Sep; 25(44):6003-14. PubMed ID: 16682955
[TBL] [Abstract][Full Text] [Related]
9. Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin.
Zhang L; Hung MC
Oncogene; 1996 Feb; 12(3):571-6. PubMed ID: 8637714
[TBL] [Abstract][Full Text] [Related]
10. Houttuyninum, an active constituent of Chinese herbal medicine, inhibits phosphorylation of HER2/neu receptor tyrosine kinase and the tumor growth of HER2/neu-overexpressing cancer cells.
Zhou NN; Tang J; Chen WD; Feng GK; Xie BF; Liu ZC; Yang D; Zhu XF
Life Sci; 2012 May; 90(19-20):770-5. PubMed ID: 22525372
[TBL] [Abstract][Full Text] [Related]
11. IGF-1 activates hEAG K(+) channels through an Akt-dependent signaling pathway in breast cancer cells: role in cell proliferation.
Borowiec AS; Hague F; Harir N; Guénin S; Guerineau F; Gouilleux F; Roudbaraki M; Lassoued K; Ouadid-Ahidouch H
J Cell Physiol; 2007 Sep; 212(3):690-701. PubMed ID: 17520698
[TBL] [Abstract][Full Text] [Related]
12. Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells.
Youngren JF; Gable K; Penaranda C; Maddux BA; Zavodovskaya M; Lobo M; Campbell M; Kerner J; Goldfine ID
Breast Cancer Res Treat; 2005 Nov; 94(1):37-46. PubMed ID: 16142439
[TBL] [Abstract][Full Text] [Related]
13. Blockade of Her2/neu binding to Hsp90 by emodin azide methyl anthraquinone derivative induces proteasomal degradation of Her2/neu.
Yan YY; Zheng LS; Zhang X; Chen LK; Singh S; Wang F; Zhang JY; Liang YJ; Dai CL; Gu LQ; Zeng MS; Talele TT; Chen ZS; Fu LW
Mol Pharm; 2011 Oct; 8(5):1687-97. PubMed ID: 21812426
[TBL] [Abstract][Full Text] [Related]
14. Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer.
Laginha KM; Moase EH; Yu N; Huang A; Allen TM
J Drug Target; 2008 Aug; 16(7):605-10. PubMed ID: 18686132
[TBL] [Abstract][Full Text] [Related]
15. [SUCI02 inhibits HER-2/neu receptor tyrosine kinase phosphorylation and growth of HER-2/neu-overexpressing breast cancer cells].
Zhu XF; Liu ZC; Xie BF; Cai LL; Yang DJ
Ai Zheng; 2003 Aug; 22(8):790-4. PubMed ID: 12917021
[TBL] [Abstract][Full Text] [Related]
16. 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes inhibit proliferation of estrogen receptor-negative breast cancer cells by activation of multiple pathways.
Vanderlaag K; Su Y; Frankel AE; Grage H; Smith R; Khan S; Safe S
Breast Cancer Res Treat; 2008 May; 109(2):273-83. PubMed ID: 17624585
[TBL] [Abstract][Full Text] [Related]
17. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
Hoeflich KP; O'Brien C; Boyd Z; Cavet G; Guerrero S; Jung K; Januario T; Savage H; Punnoose E; Truong T; Zhou W; Berry L; Murray L; Amler L; Belvin M; Friedman LS; Lackner MR
Clin Cancer Res; 2009 Jul; 15(14):4649-64. PubMed ID: 19567590
[TBL] [Abstract][Full Text] [Related]
18. Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo.
Nagasawa J; Mizokami A; Koshida K; Yoshida S; Naito K; Namiki M
Int J Urol; 2006 May; 13(5):587-92. PubMed ID: 16771730
[TBL] [Abstract][Full Text] [Related]
19. Emodin loaded solid lipid nanoparticles: preparation, characterization and antitumor activity studies.
Wang S; Chen T; Chen R; Hu Y; Chen M; Wang Y
Int J Pharm; 2012 Jul; 430(1-2):238-46. PubMed ID: 22465546
[TBL] [Abstract][Full Text] [Related]
20. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
